Elite Pharmaceuticals (OTCMKTS:ELTP) Releases Earnings Results

Elite Pharmaceuticals (OTCMKTS:ELTP) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported $0.01 EPS for the quarter, Zacks reports. Elite Pharmaceuticals had a net margin of 40.19% and a return on equity of 44.58%.

Elite Pharmaceuticals Stock Performance

OTCMKTS ELTP traded up $0.02 during trading on Friday, reaching $0.27. The company’s stock had a trading volume of 609,878 shares, compared to its average volume of 675,867. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.97 and a current ratio of 3.76. The firm has a market cap of $286.61 million, a price-to-earnings ratio of 6.65 and a beta of 0.44. Elite Pharmaceuticals has a twelve month low of $0.21 and a twelve month high of $0.68. The business’s fifty day moving average price is $0.25 and its 200-day moving average price is $0.34.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals is a specialty pharmaceutical company focused on developing, manufacturing, and marketing generic and branded drug products. Its work includes oral dosage medicines, with an emphasis on controlled-release formulations and products designed to address medication misuse. The company has developed and commercialized prescription products in several therapeutic categories, including treatments for attention-deficit/hyperactivity disorder and pain. Its business also includes advancing additional products through development and regulatory review.